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tively-the incidence and r&lion al hypomngnesmia and myww 
dial aagnosium depletion at&r heart tranrptantation. 
Bockgmund. No wial in viva study of the relation f swum 
with ti~w magn~rium has been described. Myucardial magne. 
sium depktion is aw&ated with intraceuulsr cakium overload, 
au increased incidence of cardiac arrhythmia nd changes in 
curansry vaxutature similar tu thme xen in the accekrated 
atherasctemsis that compromises gratt survival after tranSplanta- 
tion. 
Mllhoda. In a prospeeftvr study in 19 consecutive patients, 
swum and myocardiat magnesium content were measured serially 
for 9 months after heart transplantation. B&d cyclosporine was 
assayed :imultaneously. 
Raul6. The incidence 01 hypumagnesemia w s 100% during 
Bw Bmonth study period, with lowest tevelr at 3 months (mean 
0.930 vs. 0.64 mmofflitar, p < 0.002). Myocardiat magnesium 
Magneswm has been used empirically for 250 years in the 
treauuent of ventricular tachyarrhythmis, yet the mecha- 
nism of its pharmacologic action is unknown; still less is 
known of its physiologic actions (l-4). Myocsrdial magne- 
sium depletion is etiologicallp linked with sudden cardiac 
death (5,6), is associated with arrhythmia after cardiac 
surgery (7) and exacerbates arrhythmia secondary to digoxin 
to.&ity (8). In experimental models ied a magnesium- 
deficient diet, a rapidly progressive cardiomyopathy second- 
ary to calcium overload occurs tha has arteriopathic fea- 
tures in small- and medium-sized coronary arteries similar to 
those seen in accelerated corunaty disease and that compro- 
mises graft survival after heart transplantation (9-141. 
Heart transplant recipients are ?.: high risk of hypo- 
depletion dovetod in 94% and was prsistenl in 55%; the lowest 
levels occurred at 6 months (mean 33.6 vs. 30.1, pmoUg. p < 
0.04). Hypomagnesemia predakd dwreases in myocardiPl nag. 
uesium by 2 to 6 weeks. &k cyclospurtne tewlr correlsted 
pusitivoty with the decrease in serum magnesium. Clinical events 
were rare. 
Conclusions. This is the first repoti of serial meawrement al 
tissue magnesium. Persistent hypomagaewmia s invartahty ab 
computed hy myocardird mogn&m dopkiion in the tnnw 
planted heart. Reciproeut calcium overtaad aud edversa chnngcs 
in mronsry wscutatu~o would be expected from prwlour studks 
and merit further investigation. Should the impliePtions cd this 
study extend (0 the native heart, mywardtat magwiun depletion 
may contribute to the high in&deuce of fatal arrhytbmk went6 
observed in patients with heart failure, who rummanly have 
persistent hypmagnwmis. 
(I Am Co/l Cordat 1992;20:806-1.2) 
- 
magnesemia. Loop diuretic agents are used extensively 
before transplantation and are frequently required postqxr- 
atively. Cyclosportne, used as an immunosuppressive agent, 
induces significant renal magnesium wasting by an as yet 
undefined mechanism (IS). 
No clear relation between serum and myocardial ma&w- 
sium has been described. Because of potential adverse 
effects of magnesium imbalance in a previously uninvesti- 
gated high risk group, we undertook a prospective, observa- 
&al study to in&gate the incidence ofhypxnagnesemia 
after heart transplantation a d its porsibk &%i on myocar- 
dial magnesium csfitent. We also sought to observe the 
ciinical sequelae of magnesium depletion and to investigate 
the possible contribution of loop diuretic agents and cycio- 
spmine to any observed disturbance of magnesium balance. 
Methods 
Study patients and treatment. Consecutive patients enter- 
ing the cardiac transplantation Program in our hospital 
between January and October 1990 and surviving at least t 
month after transplantation were eligible for the study. All 
patients received standard immuncsuppresswe therapy wth 
cyclosporine, azathioprine and corticostermds tapered dur- 
ing 12. weeks. The dose of cyclosporine was adjusted to 
maintain trough levels withm defined hmits: 0to I week. 2SO 
to 3M) &liter; I to 4 weeks. 2M) to 250 &liter: 4 wee\s to 
3 months. 150 to 203 ueiliter: thereafter. SO 
Other therapy was p&rihed as necessary. 
to 110 &liter. 
_ 
PosttransplantaIion sludies. Endomyocardiai biopsy \va< 
performed “‘eekly for 2 months after transplantation. twice 
monthly for another month and at 6 aid 9 mouths. in 
accordance with an established protocol for the derectian of 
rejection. A symptom review and a careful drug history were 
taken at each biopsy visit. including direct questioning about 
the use of proprietary medication. A 12.lead electrocardio- 
gram was recorded and the QT interval was assessed. 
Serum magnesittm. potassirtm and crenrinine were mea- 
sured before transpisntation and at the time of each subse- 
quent sndomyocardwJ biopsy. Serum magnesium was mea- 
sured by a colorimerric method previously validated against 
atomic absorption spectroscopy. Serum potassium and cre- 
atinine were assayed with use of standard automated tech- 
niques. 
Myocardiol magrresim was measured from a single 
myocardial biopsy specimen obtained at each histologic 
assessment of rejection and analyzed with a newly described 
method specifically designed for the assay uf amall tissue 
samples (16). The lower limit of normal was defined as 
30.2 fimol/g dry weight of myocardium. This figure is derived 
from age-matched fresh cadaver control hearts analyzed 
with the same technique; the quoted figure is in keeping with 
those of other published series (5.17-19). 
Blood cyclosporine was measured at trough level (pre- 
dose) and analyzed with use of the Cycle-Tmc SP whole 
blood radioimmunoassay (Incstar). In addition. a profile of 
blood cyclospo,&+ levels was performed during the 1st 
month after tranrpizW&m. constructed from multiple sam- 
pling during a 24-h period: lhe highest recorded value was 
derignated as “peak cyclospmine level.” 
St&ties. Statistical analyses were p&aimed with a 
twc+td:ed. paired Student r te:: fur within-patient indexes. 
appmpriate regres;iun analysis and analysis of variance 
IANWA) for multivariate group analysis (201. Unless ath- 
erwise indicated, values are expressed as mean values 2 SD. 
RWllts 
Lkmegraphies. Nineteen consecutive pabents who re- 
ceived a heart transplant within the study period were 
eligible far the study. Subsequent follow-up was complete to 
9 months in IS of the I9 patients. Mean age was 50.4 years 
(range 43 to 61). Transplantation was performed because of 
intractabrc ventricular tachycardia in I patient and because 
of endqstwe heart failure in IS tatients lischemic heart 
disease in i4, dilated cardiomyopaihy in 41.’ 
Serum msgoaium. Serum magnesium was nomud at 
the time of transplantation in 15 (79%) of the 19 patients; 
0 mm Pes1.Tmnsppl.“1num (lnO” hP, 
Figure I. Prevalence of hypomagnesemia (A) and myocardia! mg. 
“esium depletion (B, in Ihe IS, 9 months after heart !r&asptamatio”. 
by 3 months, d: iY patients exhibited hypomagnesemia 
(a).? mmolfliter) on at least one occasion. The pwalence of 
hypomagnesemia during the study period is ;lluslrated in 
Figure IA. Prolonged hypnmagnesemia (persisting for 26 
weeks) occurred in all but one patient. Serum magnesium 
was severely depressed (co.6 mm&liter) in 13 patients 
(68%) within the study p&d, persisting for up to 6 weeks in 
4 patients. Mean ~erwn magnesium at baseline and at 3, 6 
and 9 months after transplantation is shown in Figure 2A. 
There was a pronwnced decrease in mean ~erttm magw 
sium to hypomagnesemic levels in the 1st 3 months after 
transplantation (0.80 + 0.16 vs. 0.64 5 0.07 mmoliliter. p < 
O.OOZ), which had only partially recovered at 6 months CO.70 
+ 0.06, p 4 0.01) despite a significant rise in serum m&w- 
sium between 3 and 6 months (p < 0.05). By 9 months mean 
seem magnesium was within nonal limits but was still 
significantly depressed over baseline at 0.72 2 0.06 mmal/ 
liter (p < 0.04). Minimal mean WUTI levels occurred at 3 
months. 
Myoeardtt -urn. The magnesium content of the 
donor heart war normal in 17 (89%) of IV patients. By 6 
aonths magnesium depletinn bad occurred in 18 (94%) of 19 
patients. Figure IB illustrates the prevalence of myocardial 
magnuium depletion during the study period. Persistent 
myocardial depletion occurred in 10 (53%) of 19 patients. 
Myocardial magnesium contert did “at increaSe in the two 
donor hearts depleted at transplas!ation. Overall. the 
ckmges in myocardial magnesium were more variable than 
those in serum magnesium (Fig. 28). Mean myocardial 
magnesium content decreased significantly during the 1st 3 
months (baseline vs. 3 months, 33.6 z 4.3 vs. 30.6 i 
4.3 pmol/S, p = 0.018). In the 17 patients wi:h normal 
mvocardial magnesium content at transtkmtation. mean 
lekls were still significantly depressed ok baseline at 6 
months (30.1 ? 5.9. D = 0.041. Proloneed mvocardial mae- 
nesium depletion (& 6 weeks) &red in nine pal& 
0%). In those patients with normal serum and myocardial 
magnesium levels at baseline, minimal mean myocardial 
levels occurred at 6 months. 
Intervelatian between serum and mwcardial maetwium. 
Litt!e relation existed between serumand myocardial mag- 
nesium levels samvIed simultaneously. The within-patient 
change in serum and myocardial ma&ium over lime is 
exemplified in Figure 3, in which the two variables are 
plotted against time in weeks. Data from three patients are 
presented as examples: Fig. 3A. normomagnesemia and 
normal myocardial magnesium content at baseline (IS of 19 
patients); Fig. 38, myocardial magnesium depletion at base- 
line (2 patients): Fig. 3C, late development of bypo- 
magnesemia with early preservation of myocardial levels (2 
patients). In general, it can be seen that changes in serum 
magnesium are mirrored 2 to 6 weeks later by similar 
alterations in myocardird magncsiom content. 
Mild hypomagnesemia (0.65 to 0.69 mmoliliter) induced 
mild myocardial depletion (28 IO 30 ~mollg) in swen of eight 
patients: myacardial magnesium levels were normal in only 
one patient throughout the rtudy. Marc significant hypo- 
magnesemia was followed by greaicr. more prolonged m)o- 
cardial drptedon in tight of nine pattents wth only mild 
depletion occurring in ihe ninth patient. Severe myacardnl 
magnesium depletion present in two patients at tra~~splanta- 
lion did not resolve until serum levels had been pcrswently 
ncn’mal for9 and I2 weeks, respecbvely. 
Other &chemical indexes. Sewrc tcnal impairment was 
not seen in 18 of 19 psiients (maximal strum creatinine 
240 ,&molflitcii. 1 he remaining padent developed acute re- 
j&on and renal failure requiring hemcdialysia and died at 
64 days. No sngnificant changer in serum creatinine ~ :re 
seen during the study period. Mean serum wtassium WBI 
4.7 mmobliter before trat:splantation. 4.3 mm&liter at :: 
months (baseline vs. 3 months. p c 0.05) and 4.5 nmoiiiiter 
at 6 months (p = NS). 
Bittretie agenls. Therapy before transplantation included 
loop diuretic agents in I8 af 19 patients. After transplanta- 
tion, diuretic agents were continued beyond t week after 
operation in IO of I8 patients. At 3 to 6 months there WBE no 
significant difference in wum magneriun. myocardial mag- 
nesium, serum potassium oi serum crxtinine between the 
group treated with diuretic agents and the untreated group. 
Cyclarporinc. Mean trough cyctospmine levels did nor 
correlate with either the serum or the myvcardial magnesium 
level within the study per&d or with the percent chznp From 
baseline of either variable. Similarly, there was little direct 
r&ion with peak cyclosporine values (available ;., IS 
patients). Patients were divided into two groups: peak cy- 
closwrine >!Xil @liter (Group A. n = 6) and <9M) uwlitcr 
(G&p B. n = 9j. There was a;trong trend toward a &ater 
decrease in serum magnesium during the 9-month period in 
patients with higher peak cyclosporine levels (percent de- 
crease in serum magnesium: Group A vs. Group B. 21.6% 
vs. 14.1%. p = 0.14). No such relation could be demon- 
strated for myocardial magnesium. 
Other drugs. Only one patienr received prescribed intra- 
venous or orat magnesium therapy. and antacid use was 
limited to magnesium-free preparations. The use of cortica- 
steroids. euther long-term or in high doses during rejection 
episodes, was not related to magnesium status. Azatbio- 
prine, aspirin, nifedipine and amiloride were similarly unre 
lated. 
Clinical ewttls. Episodes of graft rejectiu? were not 
correlated with changes in serum or myocardial magnesium 
despite changes in conicasteroid medication. Severe rejec- 
tion (grade Ill or more) was uncommon (two episodes). Two 
patients wxnplained of tremor within 3 months of transplan- 
&on. In o&patient the tremor was such that he was unable 
to hold a cup: serum magnesium was 0.51 mmollliter with 
therapeutic blood cyclospotine levels. The tremor was abol- 
ished immediateiv after an intravenous bolos iniection of 
magnesium sulfaie (8 mmoi) followed by an i&sion of 
48 mmal over 24 h. The stibsequent course is illustrated in 
Figure 4 (tbs arrows Lldicate this and another episode 
requiring intravenous administration of magnesium). Tbe 
xcond patient bad a complicated polyneuropatbg and 
tremor. Serum magnesium was 0.61 mm&liter. !n view of 
our experience with the first patient. a trial of intravenous 
magnesium was given. No symptomatic benefit was con- 
ferred. The neumlogic signs were subsequently demon- 
strated to be dae !o aminoglycaride toxicity. 
The incidence of sympromaric onhyrhmin wns verv low in 
our patients. Early after transplantation one r?tient devel- 
oped exercise-induced atrial flutter that did wt require 
treatment. Moderate ventricular ectopic activity was present 
on 24-h ECG moniwing; rw vemricular tachycardia was 
observed. This occurred in the patient who subsequently 
developed recurrent tremor secondary to hypumagnesemia 
(described above): myocardial magnesium levels are de- 
picted in Figure 4. Results of an exercise test and Wh ECG 
recording were normal at9 momhs, at which lime sentm and 
myocardial magnesium were within nomml limits. Frolonga- 
lion of the QT interval was tmt observed. 
Dixu&siin 
We have demonstrated that hypomagnesemia is very 
common atier heart transplantation managed with current 
immunosuppressive regim&s and that subsequent mywar- 
dial magnesium depletion is almost invariable. Serum and 
tissue t&tesium I&& decreased over the first Few months 
afier transplantatim; serum levels reached a nadir at absnt 3 
months and the myocardial content level was lowest at 6 
moat!.a. Serum magnesium then increased. followed by a 
later but mare rapid rise in myocardial levels. In most 
patients. the degree of hypumagnesemia was matched by a 
similxdepletion of !ttyocardial magnesium. Sigolcaot my-c- 
cardial magoesizm depiction did not develop when serum 
levels were maintained within normal limits. 
Simultaneous mezs~rernents of serum and tissue magne- 
sium are well known to correlate poorly. and our findings are 
in keeping wth lhls observation (21.22). Some reknion 
beween the two variables would be exnected physi&si- 
ally. b~l this has remained e!zive ia$ the ,~bs;a;c of 
prewous longrtudinal wlieu, Our data sugge<t that a rela- 
iion does exist. at least \r;th respect to denervated myocar- 
dium. Serum magnesium returned to normal well before 
tiswe levels w& seen to rise. This finding may explain 
the curious reponed discrepancy hetween measured scrurn 
and tissue magnesium content. It is probable that 
the magnesium depletion evide-t io the hear! ::ansplan! 
recipients represents loss of myocyle magnesium stores 
(previously complexed to phosphates). rather lban loss of 
metabolially active magnesium ions as occurs in the sym- 
pathetic response to ischemia (23). 
Cause of mawxesium deplelion. The use of furosemide 
inducss hypoma&bemia by increasing sodium delivery to 
the loop of Henle (24). In our study only 21% of patienfs had 
hypomagnesemia at the time of transplantation despite large 
doses of loop diuretics (furosemide 80 to I.wO nz$dayl. 
Within a few weeks of transplantation all paherds had 
hypomagnesemia regardless of diuretic usage. suggesting 
that furosemlde alone ~nnnot be the mechanism of magne- 
sium loss. Furthermore. no difference in magnesium sIaus 
was detected between diuretic-treated and untreated pa- 
tients. Potassium.nparing drugs such as amiloride and 
angiotensin-converting enzyme inhibitors are also magne- 
sium sparing and possibly compensate for Ihe expected 
magnesium loss. In comlilst to most previous reports of 
hypomagneremia. in our study serum potassium was main- 
tained weil within normal limits despite profound reductions 
in serum magnesium (25.26). This finding suggests thal a 
separate mechanism of magnesium imbalance may be the 
basis of the magnesium depletion observed in transplanl 
recipients. 
Thor rhis mechanism my be reiatcd fo rhr ~@cr of 
cyclosporine is demonstrated in a relation beiween peak 
cyclosporine levels occurring early ofler traosplsnta!ios 6od 
the subsequent decrease in serum ms;nerium in our study. 
Although it is gener?!ly accepted that the trough (predose) 
cycln+ne level is the more sensitive indicator of cyclo- 
spaine toxicity, and that careful manipulation of such levels 
reduces the incidence and severity of toxicity (27). we found 
no correlation between magnesium and trough cyclosporine 
levels. Recently, peak cyclosporine levels measured early 
after transplantation hsvc been shown to better relate to 
later renal function; our data are in accordance with this 
observation (28). It is known that cyclosporine selectively 
a@‘ects the tubular cells of the thick ascendicg !oop of Hale 
to produce INS toxic, magnesuric effect, although the precise 
mechanism is unclear (l&27). Our data suggest that high 
peak levels of cyclosporine are responsible for at least one of 
rbe toxic renal etTects of this drug. Hypomagncscmia also 
occurs secondary $0’ aminoglycoside renal toxicity, the 
avoidance of ciiich riquires monitor&z of b3th trough and 
peak aminoglycoside I;&. 
Further circumstantial evidence that cyclosporme may he 
B major CBUS: of hypomagnesemm in tranrplam pauems is 
sugperted hy :he generally inverse relation between thrw- 
;iiiiwiiy desirable blood trough cyclosporine leveis and 
serum magnesium over lime. AF described exlier. higher 
blood cyrlnspnrine levels are desirable m the lrt 3 months 
after transplantation and lower levels over the subsequent 9 
months. Cyclosporine renal toxicity is a dose-related phe- 
nomenon and hypomagnesemia in our study was greatest at 
3 months, the high dose period. The lower levels necessary 
over Ihe cnsoina months may be poctulated to result in less 
renal mapnesium w+age and thus explain the observed 
trend toward normalizrdion of both serum and tissue mag- 
nesium levels over this time. 
Clinical effects. Cardiac whprltrnio is reportedly rare 
after tranrplanlation. and WC found a correspondingly low 
incidence in our obrervational study despite profound snd 
persistent hgpomagnesemia (29.30). Throughout the pub- 
lishcd reports. hypomagnesemia of many causes is associ- 
ated with a resistant hypokalemia (26.31). Although we 
demonstrated a parallel relation with a statistically signifi- 
cant decrease in serum potassium occurring at the time of 
rapid magnesium flux. this decrease was not clinically sig- 
nificant and hypokalernia did not occur. We have sobse- 
quently studied bypomagnesemic transplant rccipiems with 
24-h Hotter monitoring and found a very low incidence of 
ventricular and supraventricular arrhythmia (321. Published 
reports of hypomagneremia-induced rachyarrhythmia in the 
absence of recenl hypokalemia are lacking. Arrhythmia 
unequivocally due purely to hypomagoesemia has not been 
reported, and some investigators (33) doubt that it occurs. 
Our own observations tend to suppon that doubt. 
Ncrmlogic symprvms were prominent in two patients. 
one of whom responded dramaiically to intravenous magne- 
sium therapy. The neurologic effects ofmagnesiarn depletion 
were by far lhe most prominent in a repon of hype 
magneaem;a in bone marrow transplant recipients treated 
with cyclosporine A; no cardiac effects were reported (34). 
Given the frequency of bypomagnesemia noted in our study 
and the similarity between the symptoms of cyclosporine 
neurotoxicity and those of hypomagnesemio. it is probable 
that the cause of neurologic symptoms is sometimes misdi- 
agnosed. because serum magnesium is not usually routinely 
measured in transplant patients. 
Limitations of the study. Serial measurement of myocar- 
dial elcctr~lyte content has not been previously reported, 
Reported methods of tissue analysis (17.3538) are cumber- 
some and designed for use with large samples; we (16) 
recently described a new technique specifically developed 
for the assay of the tiny tissue fragments produced by 
current in viva myocardial biopsy practice. Inaccuracies in 
such measurement are limited by the assay design; results 
outside clearly predefincd limits are discounted on the basis 
of a biphasic distribution curve and normal limits obtaiued 
from cadaver studies involving the assay of >400 biopsy 
specimens, thus addressing the difficult problem of the 
“fibrous” biopsy (usually obtained after inadvertent sam- 
pbng of an old biopsy site). We 091 have reponed an 
e.?:eIIen, correlalion with hirtologlc evaluat!on using ,hn 
technique. The varying patterns of serum and myocardial 
magnesium conteot seen in Figure 3 suggest hat the trends 
we have demonwated ax 1121 and that he techniques aed 
are appropriately sensitive. Foithermore. despite the well 
documented diminution in quality cf biopsy specimsn ‘xi:h 
time after transplantation (40). the inittal decrease in myo- 
cardial magnesium content was followed by an increase w~er 
the latter 6. to 9.month penod of the stodv. 
The effects of diuretic agents on serum m++esium are 
clearly sho,.vn 10 be miniaal. Although our evidence ior the 
involvement of cyclosporine A is in part circumstantial. oar 
data, together with the known effects of cyclosporine A on 
renal magnesium handling, results in a strong implication 
that cyclosporine A contributes ignificantly to the observed 
magnesium loss. The demonsrmtion of inappropriate urinary 
excretion of magnesium would give further weight to this 
suggestion; analyses of this factor, aithough not part of the 
oririnal study design, are oneoinz. and we will reoort the 
findings in the n&future. 
Potential longGerm cardiac &eets. In animal models, 
prolonged magnesium depletion leads to a rapidly progres- 
sive cardiomyopathy characterized by intracellular calcium 
deposition and mitochondrial disarray (9.10.41). The mter- 
relation between magnesium and calcium hes been the 
subject of much debate (42). Several postmortem studies 
($38.43) in humans have demonstrated a reciprocal relation 
between myocardial magnesium and myocardial calcium 
levels. and animal studies (44) have demczstrared the accu- 
mulation of rignificant calcium deposits within the myocytes 
of magnesium-depleted hearts, which is irreversible if mag- 
ncsium depletion is prolonged. These calcium deposits, 
which are very similar to those seen as a result of is&mm. 
result in mwcyte necrosis and myocardiai fibrosis. A restric- 
tive cardiomyopathy is a common occurrence ia the tmns- 
planted heat. Histologically, significant fibrosis is thought to 
be related to chronic rejection. Should the prolonged myo- 
cordial magnesium depletion noted in this study result in the 
same mitochootial calcium deposition. an adjunctive role of 
magnesium depletion in the development of graft fibrosis 
could be proposed. 
Accelerated coronary disease with or without hypercho- 
lesterolemia is increasmgly recognized in the “aging” trans- 
plant population. Hypomagnesemia is independently asooci- 
ated with adverse changes it, worn lipids, and although the 
mechanism of accelerated atherosclerosis is thought to be 
due at least in part to a chronic rejection process. it is 
interesting ,o note the similar obliterative arteriopathy that 
complicates the cardiomyopathy of myocardial magnesium 
depletion in animal models. 
Fhtdmgs in the native heart. Myocardial magnesium con- 
tent is lower in patients who die of ischemic heart disease 
than in those who dk of noncardiac causes, a discovery 
prompted by the ahservation that death from ischemic heart 
&se&e is more common in areas supplied by soft water. 
,han m corresponding hard water areas 1451. One study hat 
linked suoden cardiac death with myocardial magncsiom 
deplerion. noting that myocardial magnesium conlent in 
pat~n,, with chronic stable angina who died of nooc;&c 
causes did not differ fron rhat of rontrol wnjec,s ! I i). !I la 
po%it!e that persistent hypomagnesemia resuits in myocar- 
dial magnesium depiction in the oatwe ;oocx:~d kcxt. and 
has been demonstrated to occur in the transplanted dener- 
voted heart. If this is rhe case. such depletion may con,ri5n!e 
10 the high incidence of arhythmic events observed m 
oatwds wth functional class 111 and IV bca failure. a 
group in whom hypomagnesemia is common and has beer 
demonstrated 10 be an iodependen! risk factor for mort,aiity 
(46). 
Conetusiws. Hypomagnesemia occon frequently in 
heart transplant recipients and is commonly accompanied by 
depletion of myocardial intracellular magnesium. The early 
clinical effec,s of such depletion are mild and treatabte. The 
long-term scquelae are unknown. but etiologic links wi,h 
accelerated coronary ar,ery disease and myocardial fibrosis 
ar.: suoponwl by published data and merit further study. 
Arrhythmias were rare in these hypomagoesemic but 
normokalemic patients wilh a denemted hean; this finding 
is in contrd~t ,o that in hypomagnesemic patients with 
chronic (nadw) hear, failure. and funher investigadon may 
lead to XI eahanced understanding of the role of the auto- 
nomic nervoos system in the etiology of ve.ltrieular arr!tp!l- 
mia. 
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